[1]张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20-23.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
　ZHANG Jian-yuan,MIAO Wei-bing.Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):20-23.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
点击复制

电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
36
期数:
2012年第1期
页码:
20-23
栏目:
临床核医学
出版日期:
2012-01-25

文章信息/Info

Title:
Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody
作者:
张建媛;  缪蔚冰
350005 福州, 福建医科大学附属第一医院核医学科
Author(s):
ZHANG Jian-yuan;  MIAO Wei-bing
Department of Nuclear Medicine, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
关键词:
格雷夫斯病; 抗体; 促甲状腺激素受体; 化学发光测定法; 放射配体测定
Keywords:
Graves disease; Antibody;  thyrotropin receptor; Chemiluminescent measurements; Radioligand assay
DOI:
10.3760/cma.j.issn.1673-4114.2012.01.005
摘要:
目的 比较电化学发光(ECLIA)与放射性受体分析(RRA)两种方法测定血清促甲状腺激素受体抗体(TRAb)水平的差异,探讨ECLIA法检测TRAb的可行性与临床应用价值。方法 75例患者,根据临床表现及实验室检查分为格雷夫斯病(GD)症状组32例、GD缓解组23例、对照组20例,采用ECLIA和RRA两种方法分别检测各受检组血清TRAb水平。结果 ①GD症状组用ECLIA与RRA两种方法测定的TRAb值均显著高于其他两组(F=11.814,F=3.404,均P<0.05)。②两种检测方法阳性符合率为95.7%,阴性符合率为73%,总符合率为80%。对于GD症状组和对照组,两种方法的阳性率的差异都没有统计学意义(χ2=3.691,χ2=1.026,均P>0.05);而在GD缓解组中,ECLIA法阳性检出率显著高于RRA法(χ2=5.440,P<0.05)。③两种方法所测TRAb值有明显的相关性(r=0.705,P<0.01),但ECLIA法的检测值低于RRA法(Z=-4.399,P<0.01)。结论 与RRA法相比,ECLIA法具有全自动化、简便、省时、灵敏度高等优点,更适合于对临床GD患者TRAb水平的监测。
Abstract:
Objective To compare the difference between electrochemiluminescence immunoassay (ECLIA) and radioactive receptor assay(RRA)in measurement of serum thyrotropin receptor antibody(TRAb),and to explore the clinical value and feasibility of ECLIA in TRAb.Methods Seventy-five patients were selected with symptomatic Graves’ disease (GD)group 32 cases,GD in remission group 23 cases and control group 20 cases.Both ECLIA and RRA were used for the measurement of serum TRAb in all the patients.Results ①The values of TRAb with ECLIA and RRA in group of symptomatic GD were higher than those in the other two groups (F=11.814,F=3.404,P<0.05).② The positive and negative coincidence rate between the two methods were 95.7% and 73%,respectively.There was no significant difference of the positive rate between the two methods in both groups of symptomatic GD and control (χ2=3.691,χ2=1.026,P>0.05),but great difference in group of GD in remission,in which it was higher with ECLIA than with RRA (χ2=5.440,P<0.05).③ There was a good correlation between the two methods(r=0.705,P<0.01),while the value detected by ECLIA was lower than that by RRA (Z=-4.399,P<0.01).Conclusion ECLIA has the advantages of simple,convenient,timesaving,high sensitivity,and complete automatization,which is more suitable for clinical monitoring of serum TRAb for the patients with GD.

参考文献/References:

[1] Kamija K. Sludy on cntoff value seeting for differenfial diagnnsis between Graves’ disease and painless thyroiditis using the TRAb (Eleesys TIRAb) measurement via the fully automated eleclroehemi-lumineseence immunoassay system. Endoer J, 2010, 57(10):895-902.
[2] 白耀.甲状腺病学-基础与临床北京:科学技术文献出版社,2004:155.
[3] Aleksie A, Aleksie Z, Slojanovie M. TSH receplor antibodies for confirming the diagnosis and predielion of remission duration, in newly diagnosed Graves’ disease patients. Hell J Nucl Med, 2009,12(2):146-150.
[4] Schott M, Hermsen D, Broeeker-Preuss M, et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease(GD):an international multicentre trial. Glin Endocrinol(Oxf), 2009, 71(4):566-573.
[5] 许敏,陆汉魁,高云朝等.促甲状腺素受体抗体的两种免疫检测方法对比研究.标记免疫分析与临床,2010,17(4):256-259.
[6] 朱利国,浦洪波,武红玉等.促甲状腺激素、甲状腺过氧化物酶抗体和促甲状腺激素受体抗体检测在甲状腺疾病中的应用价值.标记免疫分析与临床,2010,17(4):241-243.
[7] 兰玲,施秉银.促甲状腺素受体抗体捡测技术的回顾与展望.围外医学内分泌学分册,2005,(1):45-47.
[8] Cardia MS, Lima N, Knohel M, et al. Evaluation of a coatedtube assay for antithyrotropin receptor antibodies in patients with Craves’ disease and other thyroid disorder. Thyroid, 2004, 14(4):295-300.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]王立凯,黄丽娟,潘学继,等.人附睾蛋白4单克隆抗体与免放试剂盒的制备及其对卵巢癌诊断的临床价值探讨[J].国际放射医学核医学杂志,2016,40(3):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
　Wang Likai,Huang Lijuan,Pan Xueji,et al.Preparation of monoclonal antibodies and immunoradiometric assay kit against human epididymis protein 4 and its clinical value in diagnosis of ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):183.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]汪文霞,兰晓莉,张永学.HER2的表达及其分子影像的研究进展[J].国际放射医学核医学杂志,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
　Wang Wenxia,Lan Xiaoli,Zhang Yongxue.Research and development of HER2 expression molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
[5]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[6]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[7]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
　Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[8]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[9]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[10]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[11]钟兴祥,郑吉祥,蓝冠章,等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
　ZHONG Xing-xiang,ZHENG Ji-xiang,LAN Guan-zhang,et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
[12]胡晓琳,张海燕.Graves’病患者促甲状腺素受体抗体和甲状腺刺激免疫球蛋白水平的变化及临床意义[J].国际放射医学核医学杂志,2006,30(6):350.
　HU Xiao-lin,ZHANG Hal-yan.Clinical significance and changes of TRAb and TSI assay in patients with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):350.

备注/Memo

备注/Memo:
收稿日期:2011-10-06。
通讯作者:缪蔚冰,Email:miaoweibing@I26.com
更新日期/Last Update: 1900-01-01